PHARMACY

Research finds antibiotics may fight cancer

BY Alaric DeArment

NEW YORK A new class of antibiotics may also fight cancer, according to research published in an online scientific journal.

In a study published in PLoS One, researchers from the University of Illinois at Chicago’s College of Medicine found that thiazole antibiotics may block FoxM1, a cellular protein produced in cancer cells. The drugs may also block proteasomes, which cells use to discard unused proteins.

“Since certain types of cancer may rely on a functional proteasome for growth, inhibition of proteasome activity would selectively kill these tumors,” the authors wrote.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Endo’s COO resigns

BY Alaric DeArment

CHADDS FORD, Pa. The COO of generic drug company Endo Pharmaceuticals has announced her resignation, the company announced Wednesday.

Endo said COO Nancy Wysenski will resign effective Sept. 1 to attend to family matters.

“I thank Nancy Wysenski for her contributions to the successful transition of Endo over the past two years,” CEO David Holveck said in a statement. “She has been instrumental in supporting our strong revenue growth, the diversification of the business and in strengthening our commercial capabilities.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

AstraZeneca, Forest Labs to develop ceftaroline

BY Alaric DeArment

NEW YORK Two drug companies have announced an agreement to develop a drug for treating drug-resistant bacterial infections.

New York-based Forest Labs and Anglo-Swedish drug maker AstraZeneca said Wednesday that they would work together to develop and commercialize ceftaroline in markets outside the United States, Canada and Japan.

The drug, currently in late-stage clinical trials, is designed to treat complicated skin structure infections and community-acquired bacterial pneumonia caused by bacteria such as methicillin-resistant Staphylococcus aureus and multi-drug resistant Streptococcus pneumoniae. Forest hopes to file an approval application with the Food and Drug Administration by the end of the year, while AstraZeneca hopes to file one for Europe by the end of next year.

Under the terms of the agreement, AstraZeneca will pay Forest a signing fee, royalties from sales and milestone payments and assume responsibility for development, approval and commercialization of ceftaroline in the areas covered by the agreement. Financial terms of the deal were not disclosed.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?